These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 26444434

  • 1. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
    Isoda Y, Yagi H, Satoh T, Shibata-Koyama M, Masuda K, Satoh M, Kato K, Iida S.
    PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, Kanda Y, Shitara K, Kato K, Satoh M.
    Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
    [Abstract] [Full Text] [Related]

  • 5. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
    Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, Umaña P, Benz J.
    Proc Natl Acad Sci U S A; 2011 Aug 02; 108(31):12669-74. PubMed ID: 21768335
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
    Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, Shitara K, Satoh M.
    BMC Cancer; 2009 Feb 18; 9():58. PubMed ID: 19226457
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.
    J Immunol Methods; 2011 Oct 28; 373(1-2):67-78. PubMed ID: 21855548
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
    Sakae Y, Satoh T, Yagi H, Yanaka S, Yamaguchi T, Isoda Y, Iida S, Okamoto Y, Kato K.
    Sci Rep; 2017 Oct 23; 7(1):13780. PubMed ID: 29062024
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong WL, Meng YG.
    J Immunol Methods; 2011 Feb 28; 365(1-2):132-41. PubMed ID: 21185301
    [Abstract] [Full Text] [Related]

  • 16. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
    Woodall DW, Dillon TM, Kalenian K, Padaki R, Kuhns S, Semin DJ, Bondarenko PV.
    MAbs; 2022 Feb 28; 14(1):2004982. PubMed ID: 34978527
    [Abstract] [Full Text] [Related]

  • 17. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides.
    Shoji-Hosaka E, Kobayashi Y, Wakitani M, Uchida K, Niwa R, Nakamura K, Shitara K.
    J Biochem; 2006 Dec 28; 140(6):777-83. PubMed ID: 17038352
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.
    Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, Vanderlaan M, Song A.
    MAbs; 2012 Dec 28; 4(3):326-40. PubMed ID: 22531441
    [Abstract] [Full Text] [Related]

  • 20. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K.
    Mol Immunol; 2014 Mar 28; 58(1):132-8. PubMed ID: 24334029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.